MGTA News and Press, Magenta Therapeutics Inc. From 12/10/19

Thinly traded Magenta Therapeutics ( MGTA +14.7% ) is up more than double normal volume, albeit on turnover of only 211K shares, on the heels of encouraging preclinical data on CD117-ADC, its most advanced program for the preparation of patients undergoing stem cell transplantation or ge...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its CD117-ADC patient preparation program were presented at the 61 st Annual Meeting ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its MGTA-145 stem cell mobilization program were presented at the 61 st Annual Meetin...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to participate in a fireside chat at the Evercore ISI HealthCONx Confe...

The stocks of Magenta Therapeutics (NASDAQ: MGTA) and Molecular Templates (NASDAQ: MTEM) bolted skywards last week, to the tune of 39% and 28% respectively. Cutting-edge gene-editing therapies, chimeric antigen receptor T-cell (CAR-T) treatments, and stem cell transplants all require pr...

Gainers:  Cancer Genetics CGIX  +224% . More news on: Surface Oncology, Inc., Cellectar Biosciences, Inc., Magenta Therapeutics, Inc., Stocks on the move, Read more ...

Gainers:  SAExploration (NASDAQ: SAEX )  +85% . More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., Karuna Therapeutics, Inc., Stocks on the move, Read more ...

Aravive's Reverse Merger Path to Public Company Creates Potentially Compelling Overlooked and Underfollowed Investment Opportunity If a company chooses to go public through a reverse merger instead of the more conventional IPO path, it has a higher chance to become an Overlooked and Underf...

Magenta Therapeutics (NASDAQ: MGTA ): Q3 GAAP EPS of -$0.54 in-line. More news on: Magenta Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

–Early clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of cells in 11 of 12 healthy volunteers; updated data to be presented at ASH–  –Reported first-ever successful gene therapy transplant of non-human primates with ...